Research programme: lipid metabolism disorder therapeutics - Lipid Genomics
Alternative Names: LAG3 biologicLatest Information Update: 06 Sep 2023
At a glance
- Originator University of Connecticut
- Developer Lipid Genomics
- Class Antihyperlipidaemics; Recombinant proteins; Small molecules
- Mechanism of Action CD223 antigen modulators; SCARB1 protein modulators; Scavenger receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Lipid metabolism disorders
Most Recent Events
- 06 Sep 2023 Research program is still in preclinical development in Lipid-metabolism-disorders in USA (lipid genomics pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Lipid-metabolism-disorders in USA
- 10 Jan 2019 Research programme: lipid metabolism disorder therapeutics - Lipid Genomics is available for licensing as of 10 Jan 2019. https://www.lgenomics.com/